Linus Health Showcases Role of Digital Tools and Biomarkers at Top Conference - Printable Version +- HIStalk Sponsor Announcements (https://histalk.com/forum) +-- Forum: Sponsor News (https://histalk.com/forum/forumdisplay.php?fid=1) +--- Forum: Announcements (https://histalk.com/forum/forumdisplay.php?fid=2) +--- Thread: Linus Health Showcases Role of Digital Tools and Biomarkers at Top Conference (/showthread.php?tid=2220)

Linus Health Showcases Role of Digital Tools and Biomarkers at Top Conference - Margaret Kelly - 10-02-2025 Linus Health Showcases Role of Digital Tools and Biomarkers in Early Brain Health Detection at AAFP's FMX 2025     BOSTON, Oct. 1, 2025 -- Linus Health, an AI-driven brain health company pioneering early detection of cognitive impairment and personalized intervention, will showcase its newest innovations and scientific breakthroughs at the American Academy of Family Physicians' (AAFP) Family Medicine Experience (FMX) 2025 conference taking place Oct. 5–9 in Anaheim, Calif. A centerpiece of Linus Health's participation will be a Med Talk by Chief Operating Officer John Showalter, MD, MSIS. His session, "Concern to Clarity: Using Digital Tools & Blood Biomarkers to Transform Brain Health in Primary Care," will explore how family physicians can leverage validated digital assessments alongside emerging blood biomarkers to evaluate cognitive concerns quickly and confidently at the first point of care. Showalter will highlight recent advances, including new remote assessment platforms and digital biomarkers that capture subtle behavioral changes, which can help physicians deliver earlier and more personalized brain health interventions. The presentation will take place on Tuesday, Oct. 7, from 9:40 to 9:55 a.m. PT at The Xchange: The Innovation Theater Booth #833. "Family physicians have long relied on paper-based tests to detect cognitive impairment, but those tools are often less accurate, time-consuming and lack helpful insight compared to digital solutions," Showalter said. "What we are bringing to FMX 2025 are AI-driven solutions that help clinicians move from patient concern to clinical clarity much earlier: remote validated cognitive assessments, digital biomarkers that detect risk before symptoms appear, and workflow solutions that triage more precisely. Attendees will leave with actionable methods to improve patient outcomes now." The need for such innovations is urgent. Alzheimer's disease and related dementias affect millions of Americans, with most patients first diagnosed by non-specialists. However, with lifestyle-based interventions showing enormous potential for preventing cognitive deterioration and many regions lacking adequate access to care, primary care must play a larger role in detection and management. Linus Health's AI-powered digital cognitive assessment platform is designed to fill that gap, equipping providers with scalable, science-based tools that deliver actionable clinical insights, support timely referrals, and provide personalized Brain Health Action Plans directly to patients. At Booth #1228, Linus Health will highlight its newest offerings, including: Anywhere powered by Linus Health – a flexible platform enabling validated, clinical-grade cognitive assessments both in the clinic and remotely. This dual approach supports longitudinal tracking, equitable access to early detection, and efficient use of specialist referrals by providing data that can be reviewed across care teams. New digital biomarkers – research published in the Journal of Alzheimer's Disease demonstrated that response-time biomarkers from Linus Health's digital assessments can flag dementia risk years earlier than traditional tools. UMass Chan Medical School primary care validation – findings showed that digital cognitive assessments embedded in primary care workflows helped physicians detect mild cognitive impairment (MCI) earlier, streamline referrals, and initiate proactive brain health management for at-risk patients. Person-centered assessment approaches – ongoing research emphasizes the integration of patient priorities and lived experiences into brain health evaluations for more culturally relevant and personalized care. "Early detection is vital for improving outcomes in patients with mild cognitive impairment and dementia—and it is also key to sustaining the healthcare system's ability to meet demand," said Linus Health CEO and Co-Founder David Bates, PhD. "Our latest innovations, from remote assessment delivery to digital biomarkers and health plan integrations, are helping flip the script. By empowering family physicians with evidence-based tools, we are making proactive brain health part of everyday preventive care."  Linus Health's spotlight at FMX 2025 underscores its commitment to equipping primary care with clinically validated, scalable solutions that can transform brain health management for millions of people worldwide. About Linus Health Linus Health is a Boston-based digital health company focused on transforming brain health for people across the world. By advancing how we detect and address cognitive and brain disorders – leveraging cutting-edge neuroscience, clinical expertise, and artificial intelligence – our goal is to enable a future where people can live longer, happier, and healthier lives with better brain health. Linus Health's digital cognitive assessment platform delivers a proven, practical means of enabling early detection; empowers providers with actionable clinical insights; and supports individuals with personalized action plans. We are proud to partner with leading healthcare delivery organizations, research institutions, and life sciences companies to accelerate more proactive intervention and personalized care in brain health. To learn more about our practical solutions for proactive brain health®, visit www.linushealth.com or follow us on LinkedIn. Media Contact Tara Stultz (Amendola Communications for Linus Health) tstultz@acmarketingpr.com